Dallas-based MicroTransponder is looking to treat neurological conditions with its aired Vagus Nerve Stimulation, which is designed to help patients with tinnitus as well as stroke victims. The ...

AUSTIN, Texas, Nov. 17, 2025 /PRNewswire/ -- MicroTransponder ®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim ® Paired VNS™ System for chronic stroke ...

Effective January 1, 2026, the Vivistim® procedure is assigned to New Technology Ambulatory Payment Classification 1580, with an associated national average payment of approximately $45,000 AUSTIN, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min An Austin medical technology ...

Its Serenity System is used to treat chronic tinnitus, and its Vivistim System is intended to treat poststroke upper-limb mobility issues. Frank McEachern is the company's CEO. Q: Why did you choose ...

AUSTIN, Texas, March 12, 2025 /PRNewswire/ -- Announcing a $65 million Series F financing round, MicroTransponder ®, Inc., one of the fastest-growing stroke companies, is transforming the stroke ...

Is that ringing ears bad enough that you would implant a simulator in your neck just to be free of it? For thousands of Americans, the answer seems to be yes. A series of clinical trials for an ...

MicroTransponder’s Vivistim Paired VNS system is a chest implant that helps chronic ischemic stroke survivors regain motor function in their arms and hands by stimulating the nearby vagus nerve, the ...

AUSTIN, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MicroTransponder, Inc., a commercial-stage medical device company today announced that it has changed its corporate name to Mobia Medical, Inc. ("Mobia ...

AUSTIN, Texas, Jan. 31, 2023 /PRNewswire/ -- MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services (CMS) awarded the Vivistim® Paired VNS™ System transitional ...

AUSTIN, Texas, Jan. 16, 2026 (GLOBE NEWSWIRE) -- MicroTransponder®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim® Paired VNS™ System for chronic ...

"We are pleased with CMS's decision to assign the Vivistim procedure to New Technology APC 1580, ensuring appropriate reimbursement for this groundbreaking therapy," said Richard Foust, ...